Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Articore Publishes 2026 AGM Transcript

Articore Publishes 2026 AGM Transcript

BitgetBitget2026/10/29 00:50
  • Articore reaffirmed FY27 guidance at its October 29, 2026, AGM, attended by Chair Robin Mendelson and CEO Vivek Kumar.
  • Operating EBITDA is expected at AUD 17 million–23 million, compared with AUD 16.4 million in FY26.
  • FY27 guidance targets operating expenses of AUD 79 million–85 million, with gross profit after paid acquisition margin at 27%–30%.
  • FY26 EBIT reached AUD 10.3 million, reversing a prior-year loss of AUD 9.8 million.
  • A strategic review concluded that remaining independent offered the most compelling route to long-term shareholder value.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Articore Group Ltd. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss